Inhibitor of collagen-stimulated platelet aggregation

US5710131A · kind A · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Jurgen Hemberger · Aschaffenburg, DE
• Guido Melzer · Hofheim, DE

Key dates

• Filing date: Feb 28, 1995
• Grant date: Jan 20, 1998
• Expiry date: Feb 28, 2015

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/858
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A protein isolated from crude extracts of Hirudo medicinalis is disclosed, which strongly inhibits the binding to collagen of platelets and their subsequent activation, which leads to platelet aggregation and thrombus formation. Additionally the protein prevents binding of von Willebrand factor to collagen. Described is a method for isolation and purification of the protein as well as its use for blocking collagen-stimulated platelet aggregation. The new protein (Brandinin) has a molweight of approximately 15 kD, binds to collagen but has no collagen-cleaving activity. The protein is useful in the prophylaxis, prevention and treatment of thrombotic diseaeses and for coating of blood-contacting materials, rendering them thromboresistant.